Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in wet age-related macular degeneration
NCT01255774Phase 3Unknown
- Sponsor
- New York Eye and Ear Infirmary of Mount Sinai
- Start
- Jun 2007
- Primary completion
- Dec 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by New York Eye and Ear Infirmary of Mount Sinai. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01255774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255774.